Equity Distribution Acquisition Corp. (NYSE:EQD.U) announced this afternoon that it will not complete a business combination and will instead redeem all shares.
The SPAC anticipates that the public shares will cease trading as of the close of business on September 16, 2022, and will redeem all of its outstanding shares effective as of the close of business on September 19. Shareholders shortly thereafter are anticipated to receive $10.01 per share.
Equity Distribution, which priced an upsized IPO of $360 million nearly two years ago in September 2020, intended to find a target valued between $1 billion and $1.5 billion in the industrial technology space, but said that it was unable to find a business aligned with its goals.
Equity Distribution marks the 16th SPAC liquidation so far in 2022, and the 4th in August thus far. The tech-focused SPAC was led by Chairman Sam Zell, CEO and Director Bill Galvin, CFO Philip Tinkler, and Secretary Joseph Miron.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...